FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3146679019> ?p ?o ?g. }

• W3146679019 abstract "Radiation brain necrosis (RBN) is a serious complication in patients receiving radiotherapy for intracranial disease. Many studies have investigated the efficacy and safety of bevacizumab in patients with RBN. In the present study, we systematically reviewed the medical literature for studies reporting the efficacy and safety of bevacizumab, as well as for studies comparing bevacizumab with corticosteroids.We searched PubMed, Cochrane library, EMBASE, and ClinicalTrials.gov from their inception through 1 March, 2020 for studies that evaluated the efficacy and safety of bevacizumab in patients with RBN. Two investigators independently performed the study selection, data extraction, and data synthesis.Overall, the present systematic review included 12 studies (eight retrospective, two prospective, and two randomized control trials [RCTs]) involving 236 patients with RBN treated who were treated with bevacizumab. The two RCTs also had control arms comprising patients with RBN who were treated with corticosteroids/placebo (n=57). Radiographic responses were recorded in 84.7% (200/236) of patients, and radiographic progression was observed in 15.3% (36/236). Clinical improvement was observed in 91% (n=127) of responding patients among seven studies (n=113). All 12 studies reported volume reduction on T1 gadolinium enhancement MRI (median: 50%, range: 26%-80%) and/or T2 FLAIR MRI images (median: 59%, range: 48%-74%). In total, 46 responding patients (34%) had recurrence. The two RCTs revealed significantly improved radiographic response in patients treated with bevacizumab (Levin et al.: p = 0.0013; Xu et al.: p < 0.001). Both also showed clinical improvement (Levin et al.: NA; Xu et al.: p = 0.039) and significant reduction in edema volume on both T1 gadolinium enhancement MRI (Levin et al.: p=0.0058; Xu et al.: p=0.027) and T2 FLAIR MRI (Levin et al.: p=0.0149; Xu et al.: p < 0.001). Neurocognitive improvement was significantly better after 2 months of treatment in patients receiving bevacizumab than in those given corticosteroids, as assessed by the MoCA scale (p = 0.028). The recurrence rate and side effects of the treatments showed no significant differences.Patients with RBN respond to bevacizumab, which can improve clinical outcomes and cognitive function. Bevacizumab appears to be more efficacious than corticosteroid-based treatment. The safety profile was comparable to that of the corticosteroids." @default.
• W3146679019 created "2021-04-13" @default.
• W3146679019 creator A5001960617 @default.
• W3146679019 creator A5059040478 @default.
• W3146679019 creator A5065166722 @default.
• W3146679019 creator A5081383244 @default.
• W3146679019 creator A5082832139 @default.
• W3146679019 creator A5086533374 @default.
• W3146679019 date "2021-03-25" @default.
• W3146679019 modified "2023-10-11" @default.
• W3146679019 title "Bevacizumab Treatment of Radiation-Induced Brain Necrosis: A Systematic Review" @default.
• W3146679019 cites W1131275742 @default.
• W3146679019 cites W1934448938 @default.
• W3146679019 cites W1964504973 @default.
• W3146679019 cites W1964928514 @default.
• W3146679019 cites W1965533992 @default.
• W3146679019 cites W1967963000 @default.
• W3146679019 cites W1975152788 @default.
• W3146679019 cites W1979423827 @default.
• W3146679019 cites W1981308794 @default.
• W3146679019 cites W1982841952 @default.
• W3146679019 cites W1989822957 @default.
• W3146679019 cites W1991407037 @default.
• W3146679019 cites W1999224976 @default.
• W3146679019 cites W2004575539 @default.
• W3146679019 cites W2006202974 @default.
• W3146679019 cites W2013436479 @default.
• W3146679019 cites W2014769480 @default.
• W3146679019 cites W2015042035 @default.
• W3146679019 cites W2040905251 @default.
• W3146679019 cites W2045551985 @default.
• W3146679019 cites W2050272837 @default.
• W3146679019 cites W2054083830 @default.
• W3146679019 cites W2058421556 @default.
• W3146679019 cites W2059848076 @default.
• W3146679019 cites W2073124329 @default.
• W3146679019 cites W2073251038 @default.
• W3146679019 cites W2083128109 @default.
• W3146679019 cites W2084926770 @default.
• W3146679019 cites W2094522722 @default.
• W3146679019 cites W2096053529 @default.
• W3146679019 cites W2098923148 @default.
• W3146679019 cites W2100051910 @default.
• W3146679019 cites W2113135062 @default.
• W3146679019 cites W2114270026 @default.
• W3146679019 cites W2119430710 @default.
• W3146679019 cites W2127609491 @default.
• W3146679019 cites W2136963436 @default.
• W3146679019 cites W2142364509 @default.
• W3146679019 cites W2142651198 @default.
• W3146679019 cites W2151886675 @default.
• W3146679019 cites W2158777895 @default.
• W3146679019 cites W2159314579 @default.
• W3146679019 cites W2162640759 @default.
• W3146679019 cites W2166534891 @default.
• W3146679019 cites W2169262852 @default.
• W3146679019 cites W2169943019 @default.
• W3146679019 cites W2170744163 @default.
• W3146679019 cites W2170810978 @default.
• W3146679019 cites W2170828287 @default.
• W3146679019 cites W2171085947 @default.
• W3146679019 cites W2174482320 @default.
• W3146679019 cites W2305072766 @default.
• W3146679019 cites W2339378386 @default.
• W3146679019 cites W2508977551 @default.
• W3146679019 cites W2520491845 @default.
• W3146679019 cites W2560568735 @default.
• W3146679019 cites W2588681363 @default.
• W3146679019 cites W2589766554 @default.
• W3146679019 cites W2731821507 @default.
• W3146679019 cites W2768875143 @default.
• W3146679019 cites W2799819512 @default.
• W3146679019 cites W2801919516 @default.
• W3146679019 cites W2890480472 @default.
• W3146679019 cites W2892213319 @default.
• W3146679019 cites W2893363212 @default.
• W3146679019 cites W2909780989 @default.
• W3146679019 cites W2915024982 @default.
• W3146679019 cites W2922509192 @default.
• W3146679019 cites W2937985668 @default.
• W3146679019 cites W2952717871 @default.
• W3146679019 cites W2953673541 @default.
• W3146679019 cites W2980154752 @default.
• W3146679019 cites W2990478614 @default.
• W3146679019 cites W3043896041 @default.
• W3146679019 cites W4244519082 @default.
• W3146679019 doi "https://doi.org/10.3389/fonc.2021.593449" @default.
• W3146679019 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8027305" @default.
• W3146679019 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33842309" @default.
• W3146679019 hasPublicationYear "2021" @default.
• W3146679019 type Work @default.
• W3146679019 sameAs 3146679019 @default.
• W3146679019 citedByCount "13" @default.
• W3146679019 countsByYear W31466790192021 @default.
• W3146679019 countsByYear W31466790192022 @default.
• W3146679019 countsByYear W31466790192023 @default.
• W3146679019 crossrefType "journal-article" @default.
• W3146679019 hasAuthorship W3146679019A5001960617 @default.
• W3146679019 hasAuthorship W3146679019A5059040478 @default.
• W3146679019 hasAuthorship W3146679019A5065166722 @default.

• next